Session: SAT 532-553-Hyperandrogenic Disorders
Poster Board SAT-532
Serum was obtained daily during a normal menstrual cycle from 25 healthy women who were characterized by physical and biochemical examination (743 data-points). A single serum was obtained from 43 PCOS-patients. T was measured by LC-MS/MS and by Architect® 2ndGeneration Testosterone Immunoassay (1). Sex hormone-binding globulin was measured to calculate fT (2: Vermeulen) and FAI (100*[T]/[SHBG]).
The reference intervals (central 95%) were calculated taking the underlying data structure into account, T=0.3–1.6nmol/L and 0.5–2.0nmol/L, fT=5.2–26pmol/L and 7.2–33pmol/L, and FAI=0.4–2.9 and 0.6–4.4, by LC-MS/MS and immunoassay, respectively. In healthy subjects, T, fT, and FAI levels were significantly higher mid-cycle, although a peak was not discernable in all individuals. This indicates that application of the reference ranges is valid for all phases of the menstrual cycle. The values found in PCOS-patients were 1.5nmol/L (0.6–3.2), 31pmol/L (9–60), and 3.8 (0.8–15) (median (range)) for T, fT, and FAI, respectively, by LC-MS/MS. By immunoassay, this was 1.6nmol/L (0.7–2.9), 32pmol/L (12–62), and 4.3 (1.1–16), respectively. The area under the curve of receiver operator characteristic plots were 0.84, 0.91, and 0.91 for T, fT, and FAI, respectively, by LC-MS/MS and 0.83, 0.90, and 0.89, respectively, by immunoassay.
Apart from providing reliable reference ranges, our data confirm the importance of taking SHBG into account when assessing androgen status in patients evaluated for PCOS.
Disclosure: SB: Employee, Abbott Laboratories. Nothing to Disclose: HNB, PMS, DLK, MAB, ACH
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters